Biolyst › WVEWave Life Sciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 3, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 18.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 10 concluded trials, 30% reached completion rather than being terminated or withdrawn.
Track WVE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open WVE in the tracker
Recent history
Date Event Type Phase
September 15, 2026
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD Trial Milestone
Phase 1/Phase 2
July 30, 2026
Quarterly results filed (8-K) Earnings
—
June 27, 2026
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) Trial Milestone
Phase 1/Phase 2
May 18, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
April 28, 2026
Quarterly results filed (8-K) Earnings
—
April 21, 2026
8-K filed: Other event Filing
—
April 15, 2026
8-K filed: Material agreement, Other event Corporate
—
March 26, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
February 26, 2026
Quarterly results filed (8-K) Earnings
—
February 2, 2026
8-K filed: Other event Filing
—
January 12, 2026
Quarterly results filed (8-K) Earnings
—
December 11, 2025
8-K filed: Material agreement, Reg FD disclosure, Other event Corporate
—
December 8, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
November 17, 2025
8-K filed: Reg FD disclosure Filing
—
November 10, 2025
Quarterly results filed (8-K) Earnings
—
October 30, 2025
8-K/A filed: Reg FD disclosure, Other event Filing
—
October 29, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
September 24, 2025
8-K filed: Reg FD disclosure Filing
—
September 3, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
August 11, 2025
8-K filed: Leadership change Corporate
—
August 5, 2025
8-K filed: Reg FD disclosure Filing
—
July 30, 2025
Quarterly results filed (8-K) Earnings
—
May 8, 2025
Quarterly results filed (8-K) Earnings
—
February 13, 2025
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) Trial Milestone
Phase 1
May 24, 2024
Study of WVE-003 in Patients With Huntington's Disease Trial Milestone
Phase 1/Phase 2
June 27, 2023
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) Trial Milestone
Phase 1/Phase 2
June 27, 2023
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Trial Milestone
Phase 1/Phase 2
May 11, 2021
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease Trial Milestone
Phase 1/Phase 2
May 10, 2021
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease Trial Milestone
Phase 1/Phase 2
May 3, 2021
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease Trial Milestone
Phase 1/Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.